Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Affibody-Chiesi respiratory program is a collaborative research and development initiative between Affibody and Chiesi Farmaceutici focused on creating novel treatments for respiratory diseases. The program utilizes Affibody's proprietary protein platform to develop Affibody® molecules—small, robust engineered scaffold proteins (approximately 6 kDa) designed to bind with high affinity and selectivity to specific biological targets. These molecules are being developed for delivery via inhalation, leveraging Chiesi's specialized expertise in respiratory medicine and inhalation technology. As of early 2024, the specific molecular targets, mechanism of action, and lead candidate code names remain undisclosed by the partners.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Affibody-Chiesi respiratory program.